A detailed history of Fifth Third Bancorp transactions in Exelixis, Inc. stock. As of the latest transaction made, Fifth Third Bancorp holds 2,215 shares of EXEL stock, worth $57,479. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,215
Previous 1,938 14.29%
Holding current value
$57,479
Previous $45,000 8.89%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 22, 2024

BUY
$20.34 - $23.73 $5,634 - $6,573
277 Added 14.29%
2,215 $49,000
Q1 2024

Apr 23, 2024

BUY
$20.17 - $23.93 $242 - $287
12 Added 0.62%
1,938 $45,000
Q4 2023

Jan 19, 2024

SELL
$19.25 - $24.13 $847 - $1,061
-44 Reduced 2.23%
1,926 $46,000
Q3 2023

Oct 31, 2023

BUY
$19.04 - $22.74 $11,500 - $13,734
604 Added 44.22%
1,970 $43,000
Q2 2023

Jul 25, 2023

BUY
$18.17 - $20.48 $12,464 - $14,049
686 Added 100.88%
1,366 $26,000
Q1 2023

Apr 24, 2023

BUY
$16.3 - $19.41 $6,340 - $7,550
389 Added 133.68%
680 $13,000
Q4 2022

Jan 25, 2023

SELL
$14.96 - $17.39 $11,190 - $13,007
-748 Reduced 71.99%
291 $0
Q3 2022

Oct 25, 2022

SELL
$15.68 - $22.27 $3,747 - $5,322
-239 Reduced 18.7%
1,039 $16,000
Q2 2022

Aug 04, 2022

BUY
$17.44 - $23.16 $5,528 - $7,341
317 Added 32.99%
1,278 $27,000
Q1 2022

Apr 19, 2022

BUY
$17.03 - $22.67 $11,648 - $15,506
684 Added 246.93%
961 $22,000
Q4 2021

Feb 01, 2022

SELL
$15.84 - $21.88 $7,761 - $10,721
-490 Reduced 63.89%
277 $5,000
Q3 2021

Oct 15, 2021

BUY
$16.3 - $21.14 $5,427 - $7,039
333 Added 76.73%
767 $16,000
Q2 2021

Aug 06, 2021

SELL
$17.95 - $25.56 $1,364 - $1,942
-76 Reduced 14.9%
434 $8,000
Q1 2021

May 07, 2021

BUY
$20.53 - $25.22 $3,798 - $4,665
185 Added 56.92%
510 $12,000
Q4 2020

Feb 16, 2021

SELL
$18.39 - $24.8 $4,781 - $6,448
-260 Reduced 44.44%
325 $7,000
Q3 2020

Nov 09, 2020

BUY
$20.67 - $26.94 $12,091 - $15,759
585 New
585 $14,000
Q2 2020

Aug 05, 2020

SELL
$16.46 - $27.42 $3,292 - $5,484
-200 Closed
0 $0
Q1 2020

May 05, 2020

SELL
$14.46 - $21.8 $2,009 - $3,030
-139 Reduced 41.0%
200 $3,000
Q4 2019

Feb 14, 2020

SELL
$15.15 - $18.89 $27,270 - $34,002
-1,800 Reduced 84.15%
339 $6,000
Q3 2019

Nov 14, 2019

BUY
$17.68 - $22.65 $34,281 - $43,918
1,939 Added 969.5%
2,139 $38,000
Q1 2019

May 14, 2019

BUY
$19.6 - $24.76 $3,920 - $4,952
200 New
200 $5,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $8.35B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Fifth Third Bancorp Portfolio

Follow Fifth Third Bancorp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fifth Third Bancorp, based on Form 13F filings with the SEC.

News

Stay updated on Fifth Third Bancorp with notifications on news.